The physical impact of living with ALS presents many challenges, especially as the disease progresses. With the help of assistive technologies, people living with ALS can maintain their independence and pursue their passions for as long as possible.
In 2023, unprecedented accomplishments were made in the fight against ALS in care, research, advocacy and more. We can't wait to see what 2024 has in store towards our vision of creating a world without ALS.
Pat was a former solutions team lead at Esri, a geographic information system (GIS) company, and spent his 25-year career in GIS creatively using mapping technology to solve real-world problems in the utility industry. Forced to retire in 2018 due to the progression of his disease, he had no idea where his passion for mapping and data would take him. “After my diagnosis, I wanted to bring GIS to the ALS battle, but wasn’t sure where to start,” says Pat.
Elizabeth Bradley lost her husband Woody to ALS, and has used his passing as inspiration to pursue a Master of Science in Psychology.
To complete her research project, she needs survey responses soon!
The Allied Professionals Forum is almost here - an educational and training event where hundreds of allied health professionals come together from around the world. Its two days of extensive presentations, networking, and workshops that always leaves us feeling exhausted but at the same time re-energized and rejuvenated from hearing about all the amazing work being done around the world.
Next week at the American Academy of Neurology Meeting (AAN) in Philadelphia, Biogen will present promising results of the phase 1/2 study of its newly named investigational therapy tofersen (previously BIIB067), which is now enrolling in a phase 3 trial. Tofersen is an antisense oligonucleotide (ASO), a type of designer DNA drug, targeting SOD1.